Gufic BioScience

Which are the latest news on Gufic BioScience?

Why is Gufic BioSciences Ltd falling/rising?

As of 05-Sep, Gufic BioSciences Ltd's stock price is at 445.40, reflecting a 1.17% increase. The stock has shown strong performance with significant gains over various periods, outperforming the Sensex, and has reported impressive financial results, indicating a robust upward trend.

As of 05-Sep, Gufic BioSciences Ltd's stock price is rising, currently at 445.40, reflecting an increase of 5.15 (1.17%). The stock has demonstrated strong performance over various time frames, with a notable 8.89% increase over the past week and a 12.26% rise over the past month, significantly outperforming the Sensex, which has declined by 0.97% and 2.44% respectively during the same periods. Year-to-date, the stock has risen by 32.26%, while the Sensex has fallen by 10.21%. <BR><BR>Additionally, Gufic BioSciences has been gaining consistently, with an 8.03% return over the last five days. The stock is trading above its moving averages across multiple time frames, indicating a strong upward trend. Furthermore, the company reported positive financial results, including a 112.65% growth in profit after tax over the last six months and a high debtors turnover ratio. <BR><BR>Despite a recent decline in investor participation, as evidenced by a 39.34% drop in delivery volume, the stock remains liquid enough for trading. Overall, the combination of strong financial performance, consistent gains, and market outperformance contributes to the rising stock price of Gufic BioSciences Ltd.

Who are in the management team of Gufic BioScience?

The management team of Gufic BioScience includes Chairman & Managing Director Jayesh P Choksi, CEO Pranav J Choksi, and several whole-time directors, along with a board of non-executive and independent directors, bringing diverse expertise to the company.

The management team of Gufic BioScience includes the following members:<BR><BR>1. **Jayesh P Choksi** - Chairman & Managing Director<BR>2. **Pranav J Choksi** - Whole Time Director & CEO<BR>3. **Pankaj Gandhi** - Whole-time Director<BR>4. **Dilip Ghosh** - Whole-time Director<BR>5. **Ami Naresh Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several non-executive and independent directors:<BR><BR>1. **Shreyas Patel** - Non-Executive & Independent Director<BR>2. **Gopal Daptari** - Non-Executive & Independent Director<BR>3. **Shrirang V Vadiya** - Non-Executive & Independent Director<BR>4. **Rabi Narayan Sahoo** - Non-Executive & Independent Director<BR>5. **Anusanjiv Aurora** - Non-Executive & Independent Director<BR>6. **Balram Singh** - Non-Executive & Non-Independent Director<BR><BR>This diverse team brings a range of expertise to the company.

What does Gufic BioScience do?

Gufic BioSciences Ltd is a global pharmaceutical company in the Pharmaceuticals & Biotechnology sector, known for a wide range of services and classified as a Small Cap company. As of June 2026, it reported net sales of 261 Cr and a net profit of 22 Cr, with a market cap of INR 4,071 Cr.

Overview:<BR>Gufic BioSciences Ltd is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Gufic BioSciences Ltd was incorporated in an unspecified year and is recognized as one of the top 100 pharmaceutical companies in India. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 261 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 22 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 4,071 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 57.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.05% <BR>Debt-Equity: 0.49 <BR>Return on Equity: 9.66% <BR>Price to Book: 6.15 <BR><BR>Contact Details:<BR>Address: Shop-37 1st Flr Kamala Bhavan, Swami Nityanand Road Andheri(E Mumbai Maharashtra : 400069 <BR>Phone: 91-022-66919187/67261007/66919189 <BR>Email: info@guficbio.com <BR>Website: http://www.gufic.com

Who are the peers of the Gufic BioScience?

Gufic BioScience's peers include Orchid Pharma, Morepen Labs, FDC, Guj. Themis Bio, RPG LifeScience, Unichem Labs, Aarti Drugs, Novartis India, SMS Pharma, and Zota Health Care. In terms of returns, Morepen Labs leads with 129.51% over one year, while Gufic BioScience has a return of 13.29%.

Peers: The peers of Gufic BioScience are Orchid Pharma, Morepen Labs., FDC, Guj. Themis Bio., RPG LifeScience., Unichem Labs., Aarti Drugs, Novartis India, SMS Pharma, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Guj. Themis Bio. and Novartis India, while Average management risk is found at Orchid Pharma, Morepen Labs., FDC, RPG LifeScience., Unichem Labs., Gufic BioScience, Aarti Drugs, and SMS Pharma. Good growth is noted at Unichem Labs. and Novartis India, while Below Average growth is seen at Orchid Pharma, Morepen Labs., FDC, Guj. Themis Bio., RPG LifeScience., Gufic BioScience, Aarti Drugs, SMS Pharma, and Zota Health Care. Excellent capital structure is present at Morepen Labs., FDC, Guj. Themis Bio., RPG LifeScience., and Novartis India, while Good capital structure is found at Gufic BioScience, Aarti Drugs, and Unichem Labs., and Average capital structure is observed at SMS Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Morepen Labs. at 129.51%, while the lowest is FDC at -26.41%. Gufic BioScience's 1-year return of 13.29% is higher than FDC's but lower than Morepen Labs. Additionally, Aarti Drugs is the only peer with a negative six-month return at -12.04%.

How big is Gufic BioScience?

As of 31st August, Gufic BioSciences Ltd has a market capitalization of 4,071.00 Cr, with recent Net Sales of 981.10 Cr and a Net Profit of 73.45 Cr. The company reported Shareholder's Funds of 664.95 Cr and Total Assets of 1,342.37 Cr for the latest annual period ending in March 2026.

As of 31st August, Gufic BioSciences Ltd has a market capitalization of 4,071.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Gufic BioSciences reported Net Sales of 981.10 Cr and a Net Profit of 73.45 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had Shareholder's Funds amounting to 664.95 Cr and Total Assets of 1,342.37 Cr.

Should I buy, sell or hold Gufic BioSciences Ltd?

Are Gufic BioSciences Ltd latest results good or bad?

Gufic BioSciences Ltd's Q4 FY26 results are strong, with a 183.68% increase in net profit and a 22.83% revenue growth. However, concerns about long-term profitability and stock performance relative to the market suggest a mixed outlook.

Gufic BioSciences Ltd's latest results for Q4 FY26 indicate a strong performance overall. The company reported a net profit of ₹21.90 crores, which represents a remarkable increase of 183.68% year-on-year. Revenue also grew by 22.83%, reaching ₹251.82 crores, with an operating margin of 18.75%, the highest in seven quarters. This margin improvement reflects better operational efficiency and cost management.<BR><BR>However, while these headline figures are impressive, there are underlying concerns. The stock has underperformed the broader market over the past year, declining 14.35% compared to the Sensex's 8.40% drop. This raises questions about the sustainability of the recent recovery, especially given the company's history of erratic profitability and declining capital returns.<BR><BR>In summary, while the latest results show strong quarterly performance, the overall outlook remains mixed due to concerns about long-term profitability and valuation. Investors should weigh these factors carefully.

When is the next results date for Gufic BioSciences Ltd?

The next results date for Gufic BioSciences Ltd is 14 August 2026.

The next results date for Gufic BioSciences Ltd is scheduled for 14 August 2026.

Is Gufic BioScience overvalued or undervalued?

As of December 3, 2025, Gufic BioScience is overvalued with a PE ratio of 61.64 and a Price to Book Value of 5.56, significantly higher than its peers, indicating that its current price of 349.85 is not justified given its low ROE of 9.02% and recent stock performance.

As of 3 December 2025, Gufic BioScience has moved from an expensive to a very expensive valuation grade. The company is currently overvalued, with a PE ratio of 61.64, a Price to Book Value of 5.56, and an EV to EBITDA of 28.83. In comparison to its peers, Sun Pharma has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Divi's Lab shows a PE ratio of 68.92, indicating that Gufic's valuation is significantly higher than some competitors.<BR><BR>Despite a recent stock return of -22.78% year-to-date compared to the Sensex's 8.92%, the valuation metrics suggest that Gufic BioScience is not justified at its current price of 349.85, especially when considering its low ROE of 9.02% and a PEG ratio of 0.00. Overall, the company's financial ratios and peer comparisons reinforce the conclusion that Gufic BioScience is overvalued in the current market environment.

Is Gufic BioScience technically bullish or bearish?

As of November 21, 2025, Gufic BioScience's trend is mildly bearish, indicated by bearish MACD and moving averages, while On-Balance Volume shows some bullish activity, suggesting mixed market sentiment.

As of 21 November 2025, the technical trend for Gufic BioScience has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart, while the Bollinger Bands also reflect a mildly bearish sentiment in both time frames. Moving averages indicate a mildly bearish trend on the daily chart. KST is bearish weekly and mildly bearish monthly, and Dow Theory supports a mildly bearish outlook across both time frames. However, the On-Balance Volume (OBV) shows bullish signals on both weekly and monthly charts, indicating some buying pressure. Overall, the combination of these indicators suggests a mildly bearish sentiment with some underlying bullish activity.

How has been the historical performance of Gufic BioScience?

Gufic BioScience's historical performance for the fiscal year ending March 2025 shows increased net sales and improved cash flow, but decreased profitability with lower operating profit, profit before tax, and earnings per share compared to March 2024. Total assets and liabilities rose, indicating a stable financial position despite challenges in margins.

Answer:<BR>The historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024.<BR><BR>Breakdown:<BR>Gufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, total expenditure increased to 685.12 Cr from 660.79 Cr, leading to a decrease in operating profit (PBDIT) from 148.06 Cr to 138.32 Cr. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr, reflecting a decline in profitability. The earnings per share (EPS) also dropped from 8.59 to 6.94. On the balance sheet, total assets increased to 1,169.36 Cr from 1,092.54 Cr, while total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, indicating a stable financial position. Cash flow from operating activities improved significantly to 122.00 Cr from a negative 7.00 Cr, contributing to a net cash inflow of 14.00 Cr compared to an outflow of 27.00 Cr in the previous year. Overall, while Gufic BioScience experienced growth in sales and cash flow from operations, it faced challenges in profitability and margins.

Who are the top shareholders of the Gufic BioScience?

The top shareholders of Gufic BioScience include promoter Jayesh Pannalal Choksi with 24.62%, public shareholder Motilal Oswal Financial Services Ltd at 3.32%, mutual funds with 3.39%, 21 Foreign Institutional Investors holding 0.31%, and individual investors collectively owning 15.15%.

The top shareholders of Gufic BioScience include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jayesh Pannalal Choksi, owning 24.62% of the company. Additionally, Motilal Oswal Financial Services Ltd is the highest public shareholder, holding 3.32%. The company also has mutual funds involved through five schemes, which collectively hold 3.39%, and 21 Foreign Institutional Investors (FIIs) that hold 0.31%. Individual investors collectively own 15.15% of the shares.

Has Gufic BioScience declared dividend?

Yes, Gufic BioSciences Ltd has declared a 10% dividend, amounting to 0.1 per share, with an ex-date of September 17, 2024. The dividend yield is 0.03%, and while the company has shown significant long-term growth, it experienced a recent decline in price returns over the last six months.

Gufic BioSciences Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.1<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.03%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.6%, with a dividend return of 0%, resulting in a total return of -16.6%.<BR><BR>Over the past year, the price return was 18.87%, the dividend return was 0.03%, leading to a total return of 18.9%.<BR><BR>In the two-year period, the price return was 89.23%, with a dividend return of 0.08%, giving a total return of 89.31%.<BR><BR>For the three-year period, the price return was 66.49%, the dividend return was 0.14%, resulting in a total return of 66.63%.<BR><BR>In the four-year timeframe, the price return was 94.44%, with a dividend return of 0.22%, culminating in a total return of 94.66%.<BR><BR>Finally, over five years, the price return was 479.22%, with a dividend return of 0.58%, resulting in a total return of 479.8%.<BR><BR>Overall, Gufic BioSciences has declared a dividend while experiencing varying total returns across different periods, with significant growth over the long term despite a recent decline in the short term. The dividend yield remains low, indicating that the company may be reinvesting profits for growth rather than distributing them as dividends.